FDA approves Klygefa for adults with generalised myasthenia gravis
Posted on November 17, 2026
Alexion, AstraZeneca Rare Disease has received U.S. Food and Drug Administration approval for Klygefa in adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis.
Klygefa, also known as gefurulimab, is a dual-binding nanobody C5 inhibitor administered once weekly by subcutaneous injection using an autoinjector.
The approval was supported by results from the pivotal Phase III PREVAIL study.
At Week 26, patients receiving Klygefa achieved a statistically significant improvement from baseline in Myasthenia Gravis Activities of Daily Living score compared with placebo.
The treatment difference was -1.6 points, with a 95% confidence interval of -2.4 to -0.8 and a p value below 0.0001.
Clinical improvement was observed as early as Week 1 and was sustained through the study period.
Generalised myasthenia gravis is a rare autoimmune disease characterised by fluctuating muscle weakness and reduced muscle function.
AstraZeneca estimates that around 98,500 people in the U.S. are diagnosed with gMG, of whom approximately 81,000 are positive for anti-AChR antibodies.
Kelly Gwathmey, MD, Associate Professor in the Department of Neurology at Columbia University Vagelos College of Physicians and Surgeons and an investigator in PREVAIL, said the findings demonstrated rapid and sustained functional improvement with once-weekly self-administration.
She said the treatment provides another option for patients seeking greater control over how their therapy is administered.
Klygefa was generally well tolerated in PREVAIL.
The proportion of patients experiencing treatment-emergent adverse events was similar between the Klygefa and placebo groups, and most events were mild or moderate.
The most common treatment-emergent adverse events in patients receiving Klygefa were injection-site reactions in 12%, back pain in 8% and vomiting in 5%.
The observed safety profile was consistent with previous experience with C5 inhibitors including eculizumab and ravulizumab.
The PREVAIL data were previously presented at the Myasthenia Gravis Foundation of America Scientific Session during the 2025 AANEM Annual Meeting and published in JAMA Neurology.
Klygefa is also approved in the European Union, Japan and other countries for certain adults with generalised myasthenia gravis.
Regulatory applications based on the PREVAIL results remain under review in China and additional markets.
Related Topics and Keywords
AChR antibody, Alexion, AstraZeneca, autoimmune disease, autoinjector, Biopharma, C5 inhibitor, clinical trials, complement inhibition, FDA Approval, gefurulimab, generalised myasthenia gravis, gMG, klygefa, MG-ADL, myasthenia gravis, nanobody, neurology, pharma news, phase III, PREVAIL, rare disease, subcutaneous treatment
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















